UK adults under 30 should be offered an alternative vaccine instead of the AstraZeneca vaccine if one is available in their area and they are healthy and not at high risk for COVID-19, informs The Guardian.
The UK Medicines and Health Products Regulatory Agency (MHRA) reported Wednesday on its assessment of rare cases of thrombi in some people who had received the AstraZeneca coronavirus vaccine. The British regulator has insisted that the benefits of the AstraZeneca vaccine outweigh the risks for “the vast majority of people” and the risk of thrombosis remains very low.
A few minutes before the British regulator’s press conference, the European Medicines Agency (EMA) has reported that it has found “a possible link” with very rare cases of unusual blood clots with low blood platelets, but has reiterated that the benefits Overall vaccination risks outweigh the risks of side effects. So far, the majority of cases reported to the EMA have occurred in women under the age of 60 within two weeks of vaccination. At the moment, no specific risk factors have been confirmed and they insist that the probability of this happening is very low.
Like the EMA and the World Health Organization (WHO), as well as many experts, the British regulator has insisted on its message that the benefits of the vaccine in preventing COVID-19 far outweigh any possible risks. of blood clots.
Both the regulator and the British government have recently been urging all citizens to continue to come for vaccinations when summoned, whether to receive the AstraZeneca or Pfizer injection, the cornerstones of their rapid inoculation campaign. This Wednesday, the country has begun the deployment of its third vaccine, the one developed by Moderna, in Wales.
The MHRA noted last week that 30 cases of these rare blood clots have been identified among the 18.1 million people vaccinated with that preparation as of the end of March. Of the 30 incidents, 22 correspond to cerebral venous thrombi (CVST) and eight to other problems related to blood clotting with low platelets. Seven people have died from rare blood clots after receiving the vaccine.
The vaccine’s developers together with AstraZeneca, the University of Oxford, reported Tuesday night that it has stopped testing its vaccine in children and adolescents until the UK drug regulatory agency (MHRA) provided more. information about its possible association with blood clots. A spokesman for the university noted that “although there is no concern about safety in the pediatric clinical trial,” it has decided “to wait (to have) additional information from the MHRA in its investigation of rare cases of thrombosis before administering more vaccines.”
This Monday, the television channel Channel 4 reported, citing two sources, that the British agency was considering applying some restriction to this serum to younger people, especially those under 30 years old. The regulatory agency’s executive director, June Raine, later explained that no decision had been made and urged people to keep getting vaccinated.
Raine said there was a “thorough and detailed review of the reports of some types of blood clots about some very rare and specific types of blood clots with low levels of platelets” in people who had received the AstraZeneca vaccine.
Adam Finn, a professor of pediatrics at the University of Bristol who is also part of the Joint Committee on Vaccination and Immunization (JCVI) advising the British Government also told BBC Radio 4’s Today program that clots were being investigated “very seriously. “and” very thoroughly “. The chairman of the House of Commons Health Committee, Jeremy Hunt, had requested this Wednesday “urgently” the regulatory agency to make a decision.
Some UK Drug Safety Experts consulted this Tuesday by The Guardian They said they believed there could be a causal link between the AstraZeneca vaccine and venous brain thrombi, but also stated that the vaccination campaign should continue, with risk mitigation for women under 55 years of age.
The European Medicines Agency concluded its evaluation on Wednesday after its head of vaccine strategy, Marco Cavaleri, personally told an Italian newspaper on Tuesday that there was a “clear” link between AstraZeneca and the very rare cases of thrombi before the body was officially pronounced. In its latest update, the EMA did not rule out a cause-effect relationship, but considered that the benefits still outweighed any risk of side effects. This Wednesday, they have repeated it.
Several European countries maintain some restriction on inoculation with the preparation of the Anglo-Swedish company. Germany, based on its data, decided on March 30 to restrict the use of AstraZeneca to people over 60 years of age. Two days later, the Netherlands made the same decision. In Norway, the injection is given to people over 65 and in France 55 years. In Denmark and Sweden, the administration of this serum is suspended for the moment.